Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–47. https://doi.org/10.1161/CIRCULATIONAHA.113.005119.

Article  PubMed  Google Scholar 

Patel MR, Mahaffey KW, Garg J, ROCKET AF Investigators, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. https://doi.org/10.1056/NEJMoa1009638.

Article  CAS  PubMed  Google Scholar 

Granger CB, Alexander JH, McMurray JJV, ARISTOTLE Committees and Investigators, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. https://doi.org/10.1056/NEJMoa1107039.

Article  CAS  PubMed  Google Scholar 

Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015;132(3):194–204. https://doi.org/10.1161/CIRCULATIONAHA.114.013267.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mitchell A, Watson MC, Welsh T, et al. Effectiveness and safety of direct oral anticoagulants versus vitamin k antagonists for people aged 75 years and over with atrial fibrillation: a systematic review and meta-analyses of observational studies. J Clin Med. 2019;8(4):554. https://doi.org/10.3390/jcm8040554.

Article  CAS  PubMed Central  Google Scholar 

Ingrasciotta Y, Crisafulli S, Pizzimenti V, et al. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol. 2018;14(10):1057–69. https://doi.org/10.1080/17425255.2018.1530213.

Article  CAS  PubMed  Google Scholar 

Alexander JH, Andersson U, Lopes RD, et al. Apixaban 5mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1(6):673–81. https://doi.org/10.1001/jamacardio.2016.1829.

Article  PubMed  Google Scholar 

Girgis IG, Patel MR, Peters GR, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol. 2014;54(8):917–27. https://doi.org/10.1002/jcph.288.

Article  CAS  Google Scholar 

Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013;11(1):10. https://doi.org/10.1186/1477-9560-11-10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kubitza D, Becka M, Roth A, et al. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct Factor Xa inhibitor. J Clin Pharmacol. 2013;53(3):249–55. https://doi.org/10.1002/jcph.5.

Article  CAS  PubMed  Google Scholar 

Dent E, Hoogendijk EO, Visvanathan R, et al. Malnutrition screening and assessment in hospitalised older people: a review. J Nutr Health Aging. 2019;23(5):431–41. https://doi.org/10.1007/s12603-019-1176-z.

Article  CAS  Google Scholar 

O’Sullivan ED, Hughes J, Ferenbach DA. Renal aging: causes and consequences. J Am Soc Nephrol. 2017;28(2):407–20. https://doi.org/10.1681/ASN.2015121308.

Article  CAS  Google Scholar 

Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23(1):19–28. https://doi.org/10.1053/j.ackd.2015.08.004.

Article  PubMed  PubMed Central  Google Scholar 

Voukalis C, Lip GY, Shantsila E. Drug-drug interactions of non-vitamin K oral anticoagulants. Expert Opin Drug Metab Toxicol. 2016;12(12):1445–61. https://doi.org/10.1080/17425255.2016.1225037.

Article  CAS  PubMed  Google Scholar 

Stöllberger C. Drug interactions with new oral anticoagulants in elderly patients. Expert Rev Clin Pharmacol. 2017;10(11):1191–202. https://doi.org/10.1080/17512433.2017.1370369.

Article  CAS  PubMed  Google Scholar 

Gallo P, De Vincentis A, Pedone C, REPOSI Investigators, et al. Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. Eur J Intern Med. 2019;65:51–7. https://doi.org/10.1016/j.ejim.2019.05.002.

Article  CAS  PubMed  Google Scholar 

Kundu A, Sardar P, Chatterjee S, et al. Minimizing the risk of bleeding with NOACs in the elderly. Drugs Aging. 2016;33(7):491–500. https://doi.org/10.1007/s40266-016-0376-z.

Article  CAS  PubMed  Google Scholar 

Bayer AG. Xarelto 20 mg film-coated tablets SmPC. https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-prod-uct-information_en.pdf. Accessed 29 Mar 2023.

Bristol-Myers Squibb/Pfizer EEIG. Eliquis 5 mg film-coated tablets SmPC. https://www.ema.europa.eu/en/documents/product-infor-mation/eliquis-epar-product-information_en.pdf. Accessed 29 Mar 2023.

Barra ME, Fanikos J, Connors JM, et al. Evaluation of dose-reduced direct oral anticoagulant therapy. Am J Med. 2016;129(11):1198–204. https://doi.org/10.1016/j.amjmed.2016.05.041.

Article  CAS  PubMed  Google Scholar 

Yao X, Shah ND, Sangaralingham LR, et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69(23):2779–90. https://doi.org/10.1016/j.jacc.2017.03.600.

Article  CAS  Google Scholar 

Hanigan S, Das J, Pogue K, et al. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. 2020;49(4):636–43. https://doi.org/10.1007/s11239-020-02037-3.

Article  CAS  PubMed  Google Scholar 

Wyse DG. Pharmacotherapy for rhythm management in elderly patients with atrial fibrillation. J Interv Card Electrophysiol. 2009;25(1):25–9. https://doi.org/10.1007/s10840-008-9329-8.

Article  PubMed  Google Scholar 

Kaatz S, Ahmad D, Spyropoulos AC, Subcommittee on Control of Anticoagulation, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–26. https://doi.org/10.1111/jth.13140.

Article  CAS  Google Scholar 

Schulman S, Angerås U, Bergqvist D, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202–4. https://doi.org/10.1111/j.1538-7836.2009.03678.x.

Article  CAS  Google Scholar 

Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87. https://doi.org/10.1002/(SICI)1097-0258(19960229)15:4%3c361::AID-SIM168%3e3.0.CO;2-4.

Article  PubMed  Google Scholar 

Zhang XL, Zhang XW, Wang TY, et al. Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Qual Outcomes. 2021;14(12): e00797. https://doi.org/10.1161/CIRCOUTCOMES.121.007971.

Article  Google Scholar 

Montero-Odasso M, Speechley M. Falls in cognitively impaired older adults: implications for risk assessment and prevention. J Am Geriatr Soc. 2018;66(2):367–75. https://doi.org/10.1111/jgs.15219.

Article  Google Scholar 

McGrattan AM, McGuinness B, McKinley MC, et al. Diet and inflammation in cognitive ageing and Alzheimer’s disease. Curr Nutr Rep. 2019;8(2):53–65. https://doi.org/10.1007/s13668-019-0271-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Viticchi G, Falsetti L, Burattini M, et al. Atrial fibrillation on patients with vascular dementia: a fundamental target for correct management. Brain Sci. 2020;10(7):420. https://doi.org/10.3390/brainsci10070420.

Article  PubMed  PubMed Central  Google Scholar 

Steinberg BA, Hellkamp AS, Lokhnygina Y, ROCKET AF Steering Committee and Investigators, et al. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm. 2014;11(6):925–32. https://doi.org/10.1016/j.hrthm.2014.03.006.

Article  PubMed  PubMed Central  Google Scholar 

Flaker G, Lopes RD, Hylek E, ARISTOTLE Committees and Investigators, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014;64(15):1541–50. https://doi.org/10.1016/j.jacc.2014.07.967.

Article  CAS  PubMed  Google Scholar 

Volgman AS, Nair G, Lyubarova R, et al. Management of atrial fibrillation in patients 75 years and older: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(2):166–79. https://doi.org/10.1016/j.jacc.2021.10.037.

Article  Google Scholar 

Douxfils J, Ageno W, Samama CM, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16(2):209–19. https://doi.org/10.1111/jth.13912.

Article  CAS  PubMed  Google Scholar 

Tseng CI, Roddick AJ, Bottomley MJ, et al. Safety and pharmacokinetic profile of apixaban in end-stage renal disease: a real-world analysis. EJHaem. 2022;4(1):291–3. https://doi.org/10.1002/jha2.606.

Article  CAS  PubMed Central  Google Scholar